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IL-2 ex vivo relative to ICOS Tregs. Functional analysis revealed
that ICOS+ Tregs secreted little IFN- and IL-2 in comparison to
CD4+Foxp3 – cells. Furthermore, analysis on 38 IL-2-treated
patients at MD Anderson, we found that non-responders had a
significantly higher degree of ICOS+ Treg expansion than respon-
ders during the first cycle of IL-2 therapy, while no significant
changes in the ICOS or bulk Treg population. In conclusion,
our data suggests that tracking changes in ICOS+ Tregs early
during the course of HD IL-2 therapy may be a new predictive
biomarker of clinical outcome.
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Renal cell carcinoma (RCC) is the most widespread kidney
tumor, which originates mostly from distal kidney tubules. RCC
is the major mortality cause in excretory system cancer in adults,
and constitutes about 80% of various kidney cancers. The 5-year
survival rate is 60–70%, but lowers significantly in case of metas-
tasis formation. The tumor is relatively resistant to chemother-
apy and radiation therapy, but responds to immunotherapy.
Target drugs (e.g. sunitinib, bevacizumab, a-interferon, sorafenib)
are more preferable in RCC therapy. In most cases RCC is caused
by obesity, smoking, arterial hypertension and hereditary factors.
4 patients of Voronezh Regional Clinical Oncology Center, aged
from 50 to 75 years old were enrolled in this study. All were diag-
nosed with renal cell carcinoma confirmed by immunohisto-
chemical analysis.
Gene expression profiling was performed using Affymetrix
GeneAtlas system with Affymetrix Hunam Gene 1.1 ST DNA-
microarrays. Data moralization, statistical analysis and differen-
tially expressed genes (DEG) list creation were performed using
Partek Genomics Suite v. 6.6. DNA samples were sequenced on
Ion Proton sequencer with Comprehensive Cancer Panel primer
pool. Subsequent pathway analysis and biological interpretation
were conducted using Ingenuity Pathway Analysis system and
Ion Reporter Suite.
3528 genes were differentially expressed with expression
change more than 2 times, and 351 genes changed their expres-
sion more than 5 times (p-value <0.05).
Only mutations causing either amino-acid substitution in cor-
responding protein, open reading frame shift, or truncated tran-
script formation were taken into account. Targeted DNA
sequencing revealed 99 common mutations in normal tissues of
all test subjects. 14 mutations were localized in SDHB, TRIM33,
PDE4DIP, PBX1, ABL2, MTR, VHL, ROS1, PRKDC, CSMD3, MLLT10,
TRIP11, PER1, genes and were tumor-specific in all patients.
33 mutations were localized in promoter regions of EGFR, PDGFRA
and HNF1A genes.
The most representative metabolic and signaling pathways
according to Ingenuity knowledge base were ‘‘FXR/RXR
Activation”, ‘‘Atherosclerosis Signaling”, ‘‘LXR/RXR Activation”,
‘‘Production of NO and ROS in Macrophages”, ‘‘Cell migration
and adhesion”. Five most downregulated genes among all
patients were CALB1 (187), HPD (133), KNG1 (126), SLC36A2
(126) and PAH (122). Five most upregulated genes were
TNFAIP6 (+34), ANGPT2 (+23), SERPINE1 (+22), CP (+20), HILPDA
(+20).
Genes with mutations and differentially expressed genes were
simultaneously included in pathways analysis in order to gener-
ate gene networks with possible upstream regulators (mutated
genes) included. This allowed observing a number of gene inter-
actions not present in existing reports.
This method of genomic and transcriptomic data integration
allowed us to determine the sources of mRNA level variation. A
number of mutations and specific DEGs discovered in this study
are not registered in existing databases of annotated mutations,
which allows us to propose population heterogeneity of RCC
causes. These DNA mutations and mRNA level changes could
be used as predictive biomarkers of renal cell carcinoma.
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Background: Cancer cells attractive and activate many non-
tumoral cells, including bone marrow-derived cells, as a result
stimulate migration of this cells. Many studies demonstrate that
tumor causes active redistribution of bone marrow cells during
specific stages of cancer progression and metastasis. However,
to date how the bone marrow derived cells at primary sites is
hijacked to support tumor growth and how tumor progression
influence of bone marrow cells distribution is not understood.
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The most complete picture of the impact of tumor development
on bone marrow cells migration and distribution required to
better understanding the process of forming a tumor
microenvironment.
The objective of the present study was to investigate the
influence of growth and progression of melanoma B16F10 on
unfractionated bone marrow cells (BMCs) distribution.
Materials and Methods: There were two groups of mice in this
study: healthy + intravenously transplantation BMCs (n = 5),
B16F10 + intravenously transplantation BMCs (3 days later tumor
inoculation) (n = 5). Whole bonemarrowwas harvested frommale
C57Bl6 mice and transplanted into female recipient C57BL6 mice
bearing melanoma B16F10 or healthy female mice. After 7 and
14 days of cell transplantation (10, 17 days after tumor inocula-
tion, respectively), the animals were sacrificed by cervical disloca-
tion. The blood, tumor, lymph nodes, sentinel lymph nodes
(regional lymph nodes), lung, liver, spleen, bone marrow, brain,
heart from each animal was immediately excised and processed
for qPCR analysis. To further validated PCR measurements was
performed fluorescence microscopy section of bone marrow of
mice bearing melanoma B16F10 to detection Hoechst 33342
labeled transplanted cells.
Results: In 10 days after tumor inoculation both healthy mice
and mice bearing melanoma B16F10, 80–90% of total detected
cells were identified in spleen and bone marrow. Accumulation
of BMCs was mainly observed in spleen of healthy animals (mean
4424/100,000, standard deviation 1005/100,000), whereas spleen of
mice bearing melanoma B16F10 contained significantly smaller
number of cells (mean 947/100,000, standard deviation
203/100,000) (p < 0.001).
Accumulation of BMCs was observed mainly in the bone mar-
row of mice bearing melanoma B16F10 (mean 5554/100,000, stan-
dard deviation 925/100,000), whereas bone marrow of healthy
mice contained significantly lower number of transplanted BMCs
(mean 2193/100,000, standard deviation 921/100,000) (p < 0.001).
Tumor contained a small number of Y-positive BMCs (mean
135/100,000, standard deviation 13/100,000). Significant differ-
ences in the quantitative distribution of BMCs in other examined
organs were not found.
In 14 days after cells transplantation(17 days after tumor inoc-
ulation) 80% of cells was detected in lymph nodes of healthy mice
(mean 3190/100,000, standard deviation 756/100,000). 10%
Y-positive BMCs into bloodstream of healthymice was also found,
whereas transplanted BMCs were not found in the lymph nodes
and bloodstream of mice bearing tumor. At this time it was
revealed that bone marrow of mice bearing melanoma B16F10
contained BMCs in 50 times greater than in bone marrow of
healthy mice (mean 2309/100,000, standard deviation
695/100,000 and mean 42/100,000, standard deviation 10/100,000
respectively). Tumor of mice bearing melanoma B16 contained
large amount of Y-positive BMCs (mean 569/100,000, standard
deviation 262/100,000). The liver, spleen, lung and heart did not
contain significant amount of Y positive BMCs.
Fluorescence microscopy provided clear evidence of Hoechst
33,342 labeled transplanted cells migrated to the bone marrow
of mice bearing melanoma B16F10 and further validated our
PCR measurements. Only a small number of BMCs migrated and
engrafted to bone marrow of healthy mice, while bone marrow
of mice with melanoma B16F10 contain significant number of
transplanted BMCs 10 and 17 days after BMCs administration.
Conclusion: Thus, it is shown that melanoma B16F10 regulate
distribution of BMCs with a preferred orientation in the host bone
marrow.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.100
P64
Effect of polyclonal activators on cytokine-producing capacity of blood
immunocompetent cells in adenoma and adenocarcinoma of the
stomach
A. Sosnina, A. Vankhalsky, E. Mikhailova, T. Kunts*, N. Varaksin,
A. Autenshlyus. Institute of Molecular Biology and Biophysics,
Novosibirsk, Russian Federation
⇑
Corresponding author.
Adenoma and adenocarcinoma of the stomach are related to
precancerous states and considered as successive stages of disre-
generatory process proceeding against a background of chronic
inflammation relying on cytokine-producing function of immune
cells.
Objective: Evaluation of cytokine-producing function of blood
immunocompetent cells under the influence on polyclonal
activators in patients with adenoma and adenocarcinoma of the
stomach.
Materials and Methods: Peripheral blood of 56 patients includ-
ing 32 patients with adenomas and chronic atrophic gastritis and
24 patients with adenocarcinoma of the stomach was taken
before surgery and biopsy. Peripheral blood of 30 healthy individ-
uals was used as a control. To assess the status of the gastric
mucosa, concentrations of pepsinogen I and pepsinogen II were
determined in addition to instrumental methods. Cytokine-
producing capacity of blood cells was determined using a poly-
clonal activator (PA) composed of PHA (4 lg/ml), conA (4 lg/ml)
and LPS (2 lg/ml). Concentrations of the following cytokines:
IL-1b, IL- 1Ra, TNFa, IL-2, IL-6, IL-8, IL-10, IL-17, IL-18, MCP-1, VEGF
and IFNc in the supernatant of blood cells were measured with
enzyme-linked immunosorbent assay (ELISA). The index of
polyclonal activators unfluence (IPAI) on cytokine production
was calculated: IPAI = A/B, where A is cytokine production
induced by PA, B-spontaneous cytokine production level.
Results: In patients with stomach adenomas, serum concen-
tration of pepsinogen I and the pepsinogen I/pepsinogen II ratio
were significantly lower compared with healthy individuals
indicating the development of adenoma combined with gastric
mucosa atrophy. Pepsinogen I concentration was in inverse corre-
lation with the percentage of Ki-67 positive epithelial cells, which
was also in inverse correlation with IPAI of IFNc possessing
antiproliferative action. In patients with stomach adenomas,the
increased IPAI of receptor antagonist IL-1compared with the con-
trol was revealed, that could lead to inflammation incomplete-
ness and its torpid course. In conjunction with IPAI, increase in
IL-18 level stimulates proliferative processes and contributes to
disregeneratory changes in the stomach epithelium. Direct corre-
lation between the ability of blood cells to the produce IL-1Ra
under the PA influence and the number of metastases in the
regional lymph nodes as well as reverse correlation between IPAI
of IL-2 and the number of low differentiated cells in the tumor
56 EJC SUPPLEMENTS 13 (2015) 1–75
